Drug Overview

Catequentinib hydrochloride (also widely known in research as AL3818 or anlotinib) is an advanced cancer medicine. It acts as a Targeted Therapy or “Smart Drug,” meaning it specifically seeks out and blocks the signals that help tumors grow and survive, rather than attacking the whole body like traditional chemotherapy.

Generic Name: Catequentinib hydrochloride (also known as anlotinib)
US Brand Names: Focus V (in some international markets); US brand name is currently pending.
Drug Class: Multi-Target Receptor Tyrosine Kinase Inhibitor (Anti-angiogenic agent)
Route of Administration: Oral (Capsule)
FDA Approval Status: Currently, catequentinib hydrochloride is an investigational drug in the United States and Europe, meaning it is available primarily through clinical trials. It holds “Orphan Drug” status for certain rare cancers. However, it is fully approved by regulatory agencies in other regions, such as China, for treating advanced lung cancers and sarcomas.

What Is It and How Does It Work? (Mechanism of Action)

Catequentinib hydrochloride is a Targeted Therapy that attacks cancer from two different angles at once. Tumors act like hungry weeds; to grow rapidly, they need to build a root system of blood vessels to steal nutrients and oxygen from your body. This process of building new blood vessels is called “angiogenesis.”

At the molecular level, catequentinib is a “tyrosine kinase inhibitor” (TKI). It works by blocking specific receptor “antennas” found on the surface of both cancer cells and blood vessel cells:

VEGFR (Vascular Endothelial Growth Factor Receptor): By blocking VEGFR (specifically types 1, 2, and 3), the drug stops the tumor from sending the signals needed to build new blood vessels. This effectively starves the tumor.
FGFR and PDGFR: These are receptors that send signals deep into the cancer cell, telling it to divide and multiply. Catequentinib blocks these signaling pathways, putting the brakes on tumor growth.
c-Kit: This is a special protein known as the stem cell growth factor receptor. By blocking c-Kit, the drug causes certain types of resistant cancer cells to trigger their own death.

Because it targets multiple receptors simultaneously, it is highly effective at stopping both the tumor’s growth and cutting off its food supply.

FDA Approved Clinical Indications

Because catequentinib hydrochloride is currently in the investigational phase in the United States, it is primarily used in approved clinical trials. It is, however, approved for commercial use in other countries.

Oncological uses:

Soft Tissue Sarcoma: Investigated for advanced types like Synovial Sarcoma, Leiomyosarcoma, and Alveolar Soft Part Sarcoma.
Non-Small Cell Lung Cancer (NSCLC): Investigated for advanced lung cancers that have not responded to previous standard chemotherapy.
Ovarian Cancer: Currently being tested in late-stage (Phase 3) trials for platinum-resistant ovarian cancer.
Thyroid Cancer: Investigated for certain advanced and resistant thyroid cancers.

Non-oncological uses:

There are currently no known or approved non-cancer uses for this medication.

Dosage and Administration Protocols

Since catequentinib hydrochloride is an oral medication, it is taken by mouth at home, which makes it very convenient compared to intravenous (IV) chemotherapy.

Administration Method	Standard Trial Dosage	Frequency and Schedule
Oral (Capsule)	12 mg once daily	21-day cycles: 14 days ON the drug, followed by 7 days OFF.
Oral (Capsule – Lower Dose)	8 mg or 10 mg once daily	Used if a patient experiences side effects or is combining it with chemotherapy.

Note: Capsules should always be swallowed whole with a glass of water, ideally at the same time every day.

Dose Adjustments:

Hepatic (Liver) Insufficiency: Because this drug is processed by liver enzymes (specifically CYP3A4), doctors will lower the dose or pause treatment if blood tests show liver stress or damage.
Renal (Kidney) Insufficiency: Dose adjustments may be required for severe kidney issues, though mild kidney impairment is generally well-tolerated.

Clinical Efficacy and Research Results

Recent clinical trial data (2020–2025) shows that catequentinib is very promising, particularly for rare soft tissue cancers that are historically hard to treat.

Synovial Sarcoma (2021 Data): In the global Phase 3 “APROMISS” trial, patients taking catequentinib had a 67% lower risk of their disease progressing compared to those taking standard chemotherapy (dacarbazine). The median progression-free survival (the amount of time the cancer did not grow) was 2.89 months for catequentinib compared to 1.64 months for the standard drug. Notably, nearly 30% of patients taking catequentinib were progression-free at one year, compared to under 4% on the standard drug.
Ovarian Cancer (2022-2025 Data): Ongoing Phase 3 trials are currently testing catequentinib added to standard chemotherapy for women with resistant ovarian cancer. Early safety and efficacy profiles show it can be safely combined with traditional treatments to help control tumor growth.

Safety Profile and Side Effects

Because catequentinib targets blood vessels, its side effects are different from standard hair-loss chemotherapy.

Warnings and Precautions

While there is no official FDA “Black Box Warning” yet because it is investigational in the US, drugs in this anti-angiogenic class always carry strict medical warnings for Severe Bleeding (Hemorrhage), Gastrointestinal Perforation (a hole in the stomach or intestine wall), and Heart Rhythm Delays (QT prolongation).

Common side effects (>10%)

High Blood Pressure (Hypertension): The most common side effect, caused by the drug tightening blood vessels.
Hand-Foot Syndrome: Redness, peeling, swelling, and pain on the palms of the hands and soles of the feet.
Diarrhea: Loose or frequent bowel movements.
Fatigue: Feeling unusually tired or weak.
Thyroid Changes: Increased TSH levels in blood tests, leading to an underactive thyroid (hypothyroidism).

Serious adverse events

Pneumothorax: A collapsed lung, which has been seen in some sarcoma patients taking the drug.
Severe Bleeding: Coughing up blood, severe nosebleeds, or internal bleeding.
Cardiac Issues: Changes in the electrical activity of the heart.

Management Strategies:

For High Blood Pressure: Your doctor will likely prescribe blood pressure medicine and ask you to monitor your numbers at home daily.
For Hand-Foot Syndrome: Apply thick, moisturizing creams (like those containing urea) multiple times a day and wear padded, comfortable shoes.
For Thyroid Issues: Your doctor will check your blood regularly and may prescribe a simple daily thyroid hormone pill if your levels drop.

Connection to Stem Cell and Regenerative Medicine

Catequentinib hydrochloride plays a unique role in cancer biology by directly targeting c-Kit, which is known as the “stem cell growth factor receptor.” In many cancers, a small, stubborn group of cells acts like “cancer stem cells.” These cells hide from traditional chemotherapy and are often the reason cancer comes back after treatment ends. By blocking the c-Kit receptor, catequentinib acts as an advanced Targeted Therapy that helps destroy these dangerous cancer stem cells. While it is not a regenerative medicine itself, its ability to target stem-like pathways is a major focus of modern research in preventing tumor relapses.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

ECG (Electrocardiogram): To check your heart’s electrical rhythm before starting.
Blood Pressure Check: To ensure your blood pressure is normal and well-controlled.
Thyroid and Liver Blood Tests: To get a baseline of your organ health.
Pregnancy Test: To ensure you are not pregnant, as the drug can harm an unborn baby.

Precautions during treatment

Watch for Bleeding: Be careful when shaving with standard razors or brushing your teeth. Let your doctor know if you have unusual bruising or dark stools.
Wound Healing: Because this drug stops blood vessel growth, it can delay wound healing. You must inform your doctor to pause the medication before any surgeries or major dental work.

“Do’s and Don’ts” list

DO check your blood pressure at home every day and keep a written log for your doctor.
DO use highly effective birth control while taking this medication and for several weeks after stopping.
DO tell your medical team immediately if you experience sudden chest pain or shortness of breath.
DON’T eat grapefruit or drink grapefruit juice, as it can interact with liver enzymes and dangerously increase the levels of the drug in your body.
DON’T take new medicines, including over-the-counter pain relievers (like ibuprofen) or herbal supplements, without asking your pharmacist, as they can interact with catequentinib.

Legal Disclaimer

This guide is intended for informational and educational purposes only and does not constitute medical advice. Catequentinib hydrochloride is an investigational medication in several regions and must only be taken under the strict supervision of a qualified oncologist or clinical trial investigator. Always consult with your healthcare provider for diagnosis, treatment options, and to determine if enrolling in a clinical trial is right for you. Never disregard professional medical advice or delay seeking it because of something you have read here.